CEO's statement 'The year 2024 started successfully with solid sales in the first quarter and continued strong order intake for the coming quarter.
Production is operating at high speed ensuring that deliveries progress well. Financial results look promising and we are following our strategic plan towards profitability. Excluding goodwill amortization, the period's result was -600 KSEK and we achieved a positive EBITDA of nearly 600 KSEK, which feels reassuring.'
Reporting period
Net sales amounted to KSEK 12,803 (11,053).
Profit after financial items amounted to KSEK -10,505 (-13,668).
Cash flow from operating activities for the period amounted to KSEK -4,214 (-4,522).
Earnings per share before and after dilution amounted to
Cash and cash equivalents at the end of the period amounted to KSEK 46,347 (59,956).
Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.
Events during the period
A recently conducted study has shown that levels of serum thymidine kinase 1 (sTK1) can predict the survival of patients with metastatic prostate cancer. The study also indicates that sTK1 is useful for predicting which patients may benefit from chemotherapy with the drug docetaxel, instead of hormonal treatment.
Two abstracts regarding the clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at AACR 2024.
A new study examining the use of urine-based biomarkers, including UBC Rapid, for monitoring patients with high-risk non-muscle-invasive bladder cancer has been published.
The Nomination Committee has presented proposals for the board of directors at
Events after the period
A new patent was approved in the
Interim report
Contact:
Tel: +46 (0) 8 799 67 50
Email: anders.hultman@arocell.com
About
(C) 2024 Electronic News Publishing, source